A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients

• Main Authors: Yunfang Zhu (Author), Yuxiang Xu (Author), Haopeng Zhao (Author), Hongxin Qie (Author), Xiaonan Gao (Author), Jinglin Gao (Author), Zhangying Feng (Author), Jing Bai (Author), Rui Feng (Author), Mingxia Wang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ObjectivePyrotinb has been approved for the treatment of HER2-positive advanced or metastatic breast cancer in China. However, the plasma concentration of pyrotinb in different patients varies greatly, and in the course of treatment, if patients have intolerable adverse reactions, the drug dosage wi...